Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566525 · ClinicalTrials.gov registry record · NA
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
A NA study of Elective Cardiac Surgery, sponsored by CytoSorbents.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 8
- Study locations
NCT02566525: Completed NA study of Elective Cardiac Surgery, sponsored by CytoSorbents.
NCT02566525 is a NA study of Elective Cardiac Surgery that has completed, run by CytoSorbents. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566525, a NA study of Elective Cardiac Surgery, has completed, sponsored by CytoSorbents.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
Primary Outcome
The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU.
Conditions Studied
Interventions
- DEVICE CytoSorb
Study Locations (8)
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Kentucky
- University of Kentucky - Lexington
Maryland
- University of Maryland - Baltimore
Massachusetts
- Baystate Medical - Springfield
New Jersey
- Cooper University Hospital - Camden
New York
- Columbia University - New York
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02566525 record still lists
NCT02566525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Elective Cardiac Surgery appearing as the primary indexed condition, and to 1 intervention - of which CytoSorb is the first listed.
NCT02566525 lists 8 locations in 7 states (Pennsylvania, Kentucky, Maryland).
Frequently Asked Questions
What is clinical trial NCT02566525 about?
NCT02566525 is a clinical study titled "CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery". Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
What is the current status of trial NCT02566525?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2015-11. Estimated completion is 2016-12.
What conditions does trial NCT02566525 study?
This clinical trial studies the following conditions: Elective Cardiac Surgery.
What interventions are being tested in trial NCT02566525?
The interventions under investigation include: CytoSorb (DEVICE).
Who is sponsoring clinical trial NCT02566525?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02566525 being conducted?
This trial has 8 study locations across Kentucky, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02566525's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia